• Mashup Score: 1

    The COVID-19 pandemic, the war in Ukraine and the cost-of-living crisis have unravelled our progress on cancer survival, but we also have a significant opportunity. The ambitious but achievable goal? An average of 70% ten-year survival rates for all European patients with cancer by 2035.

    Tweet Tweets with this article
    • Ahead of the @OECD Forum Series 2022 event on Closing the Cancer Gap: Towards Better Screening and Treatment (Dec 8, 2022, 1430-1600 CET), @QUBCancerProf discusses following the data to avoid a #European #cancer crisis https://t.co/qzT6lBlNUd

  • Mashup Score: 0

    In 2017, inspired by the US Cancer Moonshot initiative, The Lancet Oncology published a Commission on cancer research priorities in the USA. Writing in a Comment reflecting on this Commission from a European perspective, Fortunato Ciardiello and Josep Tabernero remarked, “as scientists and doctors working in Europe, we…believe that The Lancet Oncology Commission presents research priorities that…

    Tweet Tweets with this article
    • Linked Comment from @TheLancetOncol Editors Márcia Costa & David Collingridge: Groundshot: a pan-#European, #patient-centred, and #data-driven approach to tackling #cancer https://t.co/7sd2Ry9Xyf #cancerresearch #cancercontrol #Europe

  • Mashup Score: 0

    The European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission by Mark Lawler and colleagues,1 which addresses Europe’s cancer research challenges, has outlined how collaborative research is vital to ensure rapid improvement in cancer care from early diagnosis to precise application of therapies. Data sharing ensures research robustness, adequate datasets for…

    Tweet Tweets with this article
    • New linked Comment on: The impact of #GDPR on #datasharing for #European #cancerresearch by Rita T Lawlor https://t.co/0XEK1voDEc #cancercontrol #Europe

  • Mashup Score: 0

    2022 – Volume  9 – Suppl 2 13th European Lupus Meeting, Stockholm (October 5–8, 2022) Oral communications S01.4 Belimumab disrupts memory B-cell trafficking in patients with systemic lupus erythematosus (27 September, 2022) EJ Arends, M Zlei, CM Tipton, Z Osmani, FJ De Bie, SW Kamerling, TJ Rabelink, I Sanz, JJ Van…

    Tweet Tweets with this article
    • This week on LSM: We are presenting the #abstracts for 13th #European #Lupus #Meeting in Stockholm (Oct 5-8 2022) https://t.co/LTXZ7Y2pzf

  • Mashup Score: 0

    2022 – Volume  9 – Suppl 2 13th European Lupus Meeting, Stockholm (October 5–8, 2022) Oral communications S01.4 Belimumab disrupts memory B-cell trafficking in patients with systemic lupus erythematosus (27 September, 2022) EJ Arends, M Zlei, CM Tipton, Z Osmani, FJ De Bie, SW Kamerling, TJ Rabelink, I Sanz, JJ Van…

    Tweet Tweets with this article
    • This week on LSM: We are presenting the #abstracts for 13th #European #Lupus #Meeting in Stockholm (Oct 5-8 2022) https://t.co/LTXZ7Y2pzf

  • Mashup Score: 0

    2022 – Volume  9 – Suppl 2 13th European Lupus Meeting, Stockholm (October 5–8, 2022) Oral communications S01.4 Belimumab disrupts memory B-cell trafficking in patients with systemic lupus erythematosus (27 September, 2022) EJ Arends, M Zlei, CM Tipton, Z Osmani, FJ De Bie, SW Kamerling, TJ Rabelink, I Sanz, JJ Van…

    Tweet Tweets with this article
    • This week on LSM: We are presenting the #abstracts for 13th #European #Lupus #Meeting in Stockholm (Oct 5-8 2022) https://t.co/LTXZ7Y2pzf